Reaffirming Buy on NovaBridge Biosciences: Differentiated Givastomig Profile, Expanded Patient Reach, and Strengthened Long-Term Value Proposition
I'm PortAI, I can summarize articles.
Analyst Andres Y. Maldonado of H.C. Wainwright has reiterated a Buy rating on NovaBridge Biosciences with a price target of $9.00. He cites the differentiated clinical profile of the lead asset, givastomig, which shows strong response rates and safety in treating HER2-negative metastatic gastric cancer. The drug's ability to activate T cells in low CLDN18.2 expression environments expands its potential patient base. Maldonado's confidence is bolstered by the planned Phase 2 trial and the company's strategic focus, justifying the Buy rating and price target increase.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments